Earlier switch to atezolizumab after run-in with vemurafenib plus cobimetinib showed promise in improving OS rates in BRAF V600–positive melanoma.
Clinical Trials
Relatlimab/Nivolumab in Melanoma Improves Brain Metastasis–Free Survival
Ahmad Tarhini, MD, PhD: This was a first-line patient population with untreated metastatic melanoma who were randomly assigned 1:1 to a fixed-dose combination of nivolumab at 480 mg and relatlimab at 160 mg [Opdualag]. This was a fixed-dose single infusion on the study given over 60 minutes.
IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib………….
SOUTH SAN FRANCISCO, Calif., Sept. 23, 2024 /PRNewswire/ — IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced positive interim Phase 2 clinical trial data for darovasertib in neoadjuvant uveal melanoma (UM) and a successful FDA Type C meeting on registrational trial design for regulatory approval in neoadjuvant UM.
Study Characterizes Skin Toxicity With Uveal Melanoma Rx
Nearly 80% of patients with metastatic uveal melanoma experienced skin toxicities with tebentafusp, a targeted immunotherapy, according to a study that also suggests that the presence of skin reactions is associated with improved survival.